Skip to main content
رجوع
Watch Compare

Neurogene Inc.

جودة البيانات: 100%
NGNE
NASDAQ Manufacturing Chemicals
KWD 20.76
▲ KWD 1.48 (7.68%)
6 months return
—
Momentum
Neutral
ROE
-33.54%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-33.54%
أعلى من متوسط القطاع (-54.49%)
ROIC-29.42%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio18.39
Interest Coverage-20665.60

التقييم

PE (TTM|NTM)
-3.51 | -3.68
أقل من متوسط القطاع (-1.50)
P/B Ratio1.20
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -78.36 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

6 محللين
Buy
+274.1%
upside to target
الحالي
KWD 20.76
Consensus Target
KWD 77.67
KWD 46.00
أدنى
KWD 180.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-3.68
ربحية السهم المستقبلية
-KWD 5.54
الإيرادات المقدّرة
0.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 1.28 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 1.08 -KWD 1.05 -KWD 0.99 -KWD 1.13 — —
Estimate -KWD 0.92 -KWD 1.06 -KWD 1.09 -KWD 1.24 -KWD 1.28 -KWD 1.21
المفاجأة -17.39% +0.47% +9.17% +8.69% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -33.54% · Net Margin: N/A
Revenue (TTM) 0.0 Net Income (TTM) -90.35 M
ROE -33.54% ROA -30.88%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -78.36 M
ROIC -29.42% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 18.39
Debt / Equity N/A Current Ratio 18.39
Interest Coverage -20665.60 Asset Turnover 0.00
Working Capital 255.81 M Tangible Book Value 265.54 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3.51 · EV/EBITDA: N/A
P/E Ratio -3.51 Forward P/E -3.68
P/B Ratio 1.20 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.69%
Market Cap 317.40 M Enterprise Value 246.40 M

Per Share

EPS: -4.24 · FCF/Share: -5.03
EPS (Diluted TTM) -4.24 Revenue / Share 0.00
FCF / Share -5.03 OCF / Share -4.96
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 86.72% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 86.72%
SBC-Adj. FCF -91.65 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 925,000.0 — — —
Net Income -90.35 M -75.14 M -36.32 M -57.56 M -60.69 M
EPS (Diluted) -4.24 -4.28 2.93 -1.04 -1.10
Gross Profit — — — — —
Operating Income -103.33 M -82.61 M -55.58 M -59.10 M -60.70 M
EBITDA — — — — —
R&D Expenses 75.01 M 60.92 M 44.39 M 41.13 M —
SG&A Expenses — — — — —
D&A 3.04 M 3.20 M 3.26 M 1.56 M 1.31 M
Interest Expense 5,000.0 12,000.0 12,000.0 1.58 M —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 288.60 M 335.73 M 222.57 M 115.95 M 163.26 M
Total Liabilities 23.72 M 25.36 M 36.55 M 21.62 M 20.40 M
Shareholders' Equity 264.89 M 310.38 M 186.02 M 94.33 M 142.86 M
Total Debt — — — — —
Cash & Equivalents 103.85 M 136.59 M 148.21 M 37.89 M 142.47 M
Current Assets 271.77 M 315.92 M 200.35 M 99.13 M 143.99 M
Current Liabilities 16.41 M 15.16 M 22.97 M 11.06 M 8.64 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -3.5 -1.5
P/B 1.2 1.6
ROE % -33.5 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock
BBC logo BBC Virtus Biotech Clinical Trials ETF
0.86% weight
MSGRX MSGRX
0.20% weight
MSGGX MSGGX
0.20% weight
MISGX MISGX
0.20% weight
MSGAX MSGAX
0.20% weight
MSGCX MSGCX
0.20% weight
VVICX VVICX
0.01% weight
IRCIX IRCIX
0.01% weight
IRSIX IRSIX
0.01% weight
IIRSX IIRSX
0.01% weight